Date: 2013-10-23
Type of information: Development agreement
Compound:
Company: Umecrine Cognition (Sweden) Clevexel Pharma (France)
Therapeutic area: Hepatic diseases - CNS diseases
Type agreement: development
Action mechanism:
Disease: hepatic encephalopathy
Details: * On October 23, 2013, Umecrine Cognition, a Karolinska Development portfolio company, has announced that the company has entered into a partnering agreement with CleveXel Pharma regarding the development of its lead program in hepatic encephalopathy. According to the agreement, CleveXel Pharma will co-fund the development of Umecrine Cognition’s lead program in hepatic encephalopathy through investments in shares in the company. Umecrine Cognition will use the proceeds for payments for services that CleveXel provides for the preclinical and clinical development through to proof-of-concept. If the whole program is executed CleveXel will hold up to 15 percent of the shares in Umecrine Cognition by mid-year 2014.
Financial terms:
Latest news:
